MedTrace Logo

Telatinib Safety and Pharmacokinetics Study in China Patients With Advanced Solid Tumors

NCT03175497 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2019-05-13

No results posted yet for this study

Summary

The purpose of this China Phase I bridging study is to to evaluate the safety, tolerability and pharmacokinetic profile of telatinib in China patients with advanced solid tumor

Conditions

  • Solid Tumor, Adult

Interventions

DRUG

Telatinib Mesylate

Telatinib mesylate tablets will be administrated twice a day orally

Sponsors & Collaborators

  • Fountain Medical Development Co., Ltd.

    collaborator INDUSTRY

  • Taizhou EOC Pharma Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Tianshu Liu, MD · Fudan University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-25
Primary Completion
2018-08-15
Completion
2018-08-15
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03175497 on ClinicalTrials.gov